Antagonistic anti-CD40 antibodies and methods of antagonizing CD40 activity
US11220550B2 · kind B2 · utility
5Cited by
11References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 24, 2018 |
| Grant date | Jan 11, 2022 |
| Priority date | — |
| Expiry date | Jun 5, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosure provides for antibodies that bind CD40, including a humanized antibody and a chimeric antibody with different Fc domains. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.